Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19248Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kalogirou, M. | en |
| dc.contributor.author | Tsimihodimos, V. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T18:58:07Z | - |
| dc.date.available | 2015-11-24T18:58:07Z | - |
| dc.identifier.issn | 1879-0712 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19248 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Anticholesteremic Agents/pharmacology/therapeutic use | en |
| dc.subject | Atherosclerosis/*drug therapy | en |
| dc.subject | Azetidines/*pharmacology/*therapeutic use | en |
| dc.subject | Biological Markers/metabolism | en |
| dc.subject | Disease Models, Animal | en |
| dc.subject | Endothelium, Vascular/drug effects | en |
| dc.subject | Humans | en |
| dc.subject | Inflammation/*drug therapy/metabolism | en |
| dc.subject | Inflammation Mediators | en |
| dc.subject | Lipid Metabolism/*drug effects | en |
| dc.subject | Platelet Aggregation/drug effects | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Pleiotropic effects of ezetimibe: do they really exist? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.ejphar.2010.02.003 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20152830 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0014299910000865/1-s2.0-S0014299910000865-main.pdf?_tid=66ea5c63c740e7b39c359383c65d1fa6&acdnat=1334038252_e71473eeda77cb3702f5ce4df8928a5e | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | Ezetimibe represents a new lipid lowering agent which inhibits cholesterol absorption. It effectively reduces low-density lipoprotein cholesterol when administered either alone or in combination with statins. However, its effect on cardiovascular mortality remains under question since it failed to demonstrate any significant changes in the primary endpoints of the recently published ENHANCE and SEAS studies. A possible explanation for this unsuccessful outcome is that ezetimibe lacks pleiotropic effects. This article aims to review the potential pleiotropic effects of the drug mainly on inflammation markers, lipoprotein subfractions and endothelial function. | en |
| heal.journalName | European Journal of Pharmacology | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Kalogirou-2010-Pleiotropic effects.pdf | 229.39 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
